Neurocrine Biosciences upgraded by Piper Sandler with a new price target

8/29/24 7:34:42 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Piper Sandler upgraded Neurocrine Biosciences from Neutral to Overweight and set a new price target of $159.00 from $131.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NBIX

Date	Price Target	Rating	Analyst
4/15/2025	$138.00	Hold → Buy	Needham
4/14/2025	$137.00	Sector Perform → Outperform	RBC Capital Mkts
2/11/2025	$138.00	Hold	Deutsche Bank
10/10/2024	$155.00	Outperform	Raymond James
8/29/2024	$131.00 → $159.00	Neutral → Overweight	Piper Sandler
4/24/2024	$140.00 → $170.00	Equal Weight → Overweight	Wells Fargo
12/13/2023	$127.00	Neutral	Citigroup
12/12/2023	$136.00	Buy	Deutsche Bank